FRANKFURT, March 26 (Reuters) – Germany’s Evonik
has been evaluating Clariant and other speciality
chemicals companies for a potential takeover bid, sources told
Reuters, adding that it had yet to decide how to proceed.
The Financial Times reported on Thursday that Evonik was
considering a bid for Swiss peer Clariant to create a group with
a market value of more than 20 billion euros ($22 billion), but
several sources familiar with the situation said it had also
looked at DSM and Croda.
FRANKFURT (Reuters) – Germany’s Bayer said it was considering strategic options for its home and garden consumer products business, maker of Baby Bio plant feed, as its crop protection arm focuses on professional customers.
People familiar with the matter told Reuters that Bayer was preparing to sell the business and was gauging the interest of prospective buyers, which could be private equity or industry players. The business generated 220 million euros ($236 million) in annual sales last year.
COLOGNE, Germany, March 19 (Reuters) – German chemicals
group Lanxess unveiled more cutbacks on Thursday,
shedding about 140 jobs in rubber production and acknowledging
its quest for a strategic partner would likely take until the
second half of the year.
The company, the world’s No.1 maker of synthetic rubber,
said as early as May last year it would seek a strategic partner
for its hard-pressed rubber division, shortly after Chief
Executive Matthias Zachert replaced Axel Heitmann at the helm.
FRANKFURT, March 18 (Reuters) – German carbon specialist SGL
Carbon stepped up cost cutting efforts again to
grapple with a difficult market for graphite electrodes used in
The group on Wednesday lifted the overall savings target of
its ongoing efficiency programme to 240 million euros ($254
million), having already increase the target to 200 million from
150 million in September.
MUNICH, March 16 (Reuters) – German industrial gases firm
Linde expects adjusted core profit to rise in 2015
thanks to new gas supply projects due to come on stream, but
warned lower oil prices and geo-political tensions were
The company, which processes gases for clients including
steelmakers, food companies and petrochemical groups, is
benefiting from output capacity built up with higher-than-usual
investment in plant and equipment over the past three years.
FRANKFURT, March 12 (Reuters) – German potash miner K+S
raised its dividend for 2014 after a rebound in
prices of the fertiliser ingredient brightened the outlook for
the company’s earnings this year, sending its shares higher.
K+S said it would pay a dividend of 0.90 euros ($0.96) per
share for 2014, up from 0.25 euros a year earlier and exceeding
a market forecasts of 0.64 euros.
FRANKFURT (Reuters) – Bayer (BAYGn.DE: Quote, Profile, Research, Stock Buzz) aims to increase sales of its main healthcare division by an annual 6 percent until 2017, with growth prospects for new drugs such as stroke prevention pill Xarelto boosting shares in Germany’s largest drugmaker.
The company, which is splitting off its plastics business, has seen sales of recently launched drugs such as eye treatment Eylea outweigh declines at its birth-control and multiple sclerosis drug businesses which face tough competition.
FRANKFURT, March 10 (Reuters) – Sana Kliniken AG, Germany’s
third-largest private-sector hospitals operator, said it would
wait for the June election of new supervisory board members at
rival Rhoen before deciding whether a possible tie-up
“We’ve been in contact and there have been talks for years
but we will calmly wait for the annual general meeting and the
structures that are to result from it,” Sana Chief Executive
Michael Philippi told journalists in a conference call.
FRANKFURT, March 10 (Reuters) – German fragrance and
flavours maker Symrise posted a better-than-expected
46 percent rise in quarterly core earnings, helped by the
takeover of pet food flavouring company Diana and a return to
sales growth at its Scent and Care unit.
Fourth-quarter earnings before interest, tax, depreciation
and amortisation (EBITDA), adjusted for one-off effects, reached
120.7 million euros ($130.2 million), the group said on Tuesday.
DARMSTADT, Germany, March 3 (Reuters) – Merck KGaA
said underlying core profit would rise slightly this year, or at
worst stagnate, as the German firm develops a cancer treatment
and its best-selling drug Rebif battles stiff competition.
Sales of Merck’s multiple sclerosis medicine Rebif slipped 5
percent in the last three months of 2014, after adjustments for
currency fluctuations. While this was a smaller decline than
expected, the company predicted more sales falls this year.